Pulmonology

 
Response to Dupilumab in Severe Asthma Predicted by Baseline FeNo
November 17, 2020

Increasing baseline FeNo levels were associated with reduced exacerbation and greater lung function improvement in dupilumab-vs-placebo-treated patients.

Increased Blood Eosinophil Counts, IgE Levels Linked to Higher Exacerbation Rates in Severe Asthma
November 17, 2020

Increased blood eosinophil counts and IgE levels are associated with higher exacerbation rates in patients with severe asthma, according to new research presented at ACAAI 2020.

Severe Asthma: A 5-question POP Quiz
November 13, 2020

Severe asthma affects 5% to 10% of adults with asthma. Find out what you know about diagnosis and treatment options for these patients with 5 no-nonsense questions.

Tezepelumab for Severe Asthma Meets Phase 3 Primary Endpoint
November 10, 2020

The novel monoclonal antibody could bring relief to millions of persons with severe, uncontrolled asthma, including those with a low eosinophil phenotype.

COPD Self-management App Reduces Exacerbations, Readmissions vs Usual Care
November 06, 2020

Use of the myCOPD app after hospitalization for acute COPD exacerbation reduced subsequent exacerbations by nearly 50%, according to study authors.

ATS 2020: Masitinib Significantly Reduces Severe Asthma Exacerbations
October 19, 2020

New research presented at the American Thoracic Society virtual symposium showed the first-in-class drug reduced severe asthma exacerbation rate by 35% vs placebo.

CVD Mortality in COPD Related to Factors Other than Lung Function Decline
October 05, 2020

In COPD patients, a new study found no association between lung function decline and individual CVD outcomes, but disease exacerbations and dyspnea were implicated.

FDA Approves First Drug to Treat Group of Rare Blood Disorders in Over 10 Years
September 30, 2020

Mepolizumab (Nucala) received a new indication for the treatment of hypereosinophilic syndrome in patients aged ≥12 years.

FDA Approves First Once-daily Single Inhaler Triple Therapy for Both Asthma, COPD Treatment
September 16, 2020

Along with COPD, fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta) is now approved for the treatment of asthma in patients aged ≥18 years.

US Adolescent E-cigarette Users at Increased Risk for COVID-19
August 17, 2020

A new survey found adolescents who have ever used e-cigarettes are 5-times more likely to receive a COVID-19 diagnosis. More results at-a-glance in our new slideshow.